Evidence map›Paper›PMID 27999284›Full record

ArticleInternational journal of molecular sciences2016

Aspirin down Regulates Hepcidin by Inhibiting NF-κB and IL6/JAK2/STAT3 Pathways in BV-2 Microglial Cells Treated with Lipopolysaccharide.

Wan-Ying Li, Fei-Mi Li, Yu-Fu Zhou, Zhong-Min Wen, Juan Ma, Ke Ya, Zhong-Ming Qian

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
  10. Article
  11. Review
  12. An improved genome assembly forCommunications biology · 2018
    Article
  13. Review
  14. Activation of spinal dorsal horn P2YJournal of pain research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wan-Ying LiLaboratory of Neuropharmacology, Fudan University School of Pharmacy, Shanghai 201203, China. lj19840208@126.com.
Fei-Mi LiLaboratory of Neuropharmacology, Fudan University School of Pharmacy, Shanghai 201203, China. lfm19910916@sina.com.
Yu-Fu ZhouLaboratory of Neuropharmacology, Fudan University School of Pharmacy, Shanghai 201203, China. zyf19850722@126.com.
Zhong-Min WenDepartment of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China. sy19871104@yahoo.com.
Juan MaLaboratory of Neuropharmacology, Fudan University School of Pharmacy, Shanghai 201203, China. mj19890412@126.com.
Ke YaSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China. yake@cuhk.edu.hk.
Zhong-Ming QianLaboratory of Neuropharmacology, Fudan University School of Pharmacy, Shanghai 201203, China. qianzhongming@fudan.edu.cn.
Fudan University · CNChinese University of Hong Kong · CNSecond Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspirin down regulates transferrin receptor 1 (TfR1) and up regulates ferroportin 1 (Fpn1) and ferritin expression in BV-2 microglial cells treated without lipopolysaccharides (LPS), as well as down regulates hepcidin and interleukin 6 (IL-6) in cells treated with LPS. However, the relevant mechanisms are unknown. Here, we investigate the effects of aspirin on expression of hepcidin and iron regulatory protein 1 (IRP1), phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and P65 (nuclear factor-κB), and the production of nitric oxide (NO) in BV-2 microglial cells treated with and without LPS. We demonstrated that aspirin inhibited hepcidin mRNA as well as NO production in cells treated with LPS, but not in cells without LPS, suppresses IL-6, JAK2, STAT3, and P65 (nuclear factor-κB) phosphorylation and has no effect on IRP1 in cells treated with or without LPS. These findings provide evidence that aspirin down regulates hepcidin by inhibiting IL6/JAK2/STAT3 and P65 (nuclear factor-κB) pathways in the cells under inflammatory conditions, and imply that an aspirin-induced reduction in TfR1 and an increase in ferritin are not associated with IRP1 and NO.

Indexed as

Interleukin-6 InhibitorsAnimalsAspirinCell LineHepcidinsInflammationInterleukin-6Iron Regulatory Protein 1Janus Kinase 2LipopolysaccharidesMiceMicrogliaNitric OxidePhosphorylationRNA, MessengerSignal TransductionAspirinHepcidinsInterleukin-6Interleukin-6 Inhibitorsinterleukin-6, mouseIron Regulatory Protein 1Jak2 protein, mouseJanus Kinase 2LipopolysaccharidesNitric OxideRela protein, mouseRNA, MessengerStat3 protein, mouseSTAT3 Transcription FactorTranscription Factor RelAaspirinhepcidinIL-6/JAK2/STAT3 pathwayiron regulatory protein 1 (IRP1)lipopolysaccharide (LPS)nitric oxide (NO)P65 (nuclear factor-κB)

Identifiers

PMID27999284
PMCPMC5187761
OpenAlexW2566434184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.